Falling Fentanyl Deaths Drive Historic 24.4% Drop in U.S. Overdose Mortality, But Stimulant and Xylazine Threats Grow
核心洞察
U.S. overdose death rates fell by 24.4% between 2023 and 2024, the first decline across all four waves of the overdose crisis, driven largely by drops in fentanyl-related fatalities.
Deaths involving fentanyl without stimulants fell from 31,193 to 19,673, while fentanyl-stimulant combination deaths dropped from 41,583 to 28,062, according to UC San Diego research published in Addiction.
Stimulant-only deaths continued rising to 18,907 in 2024, now accounting for 23.8% of overdose fatalities, while xylazine involvement in fentanyl deaths also increased.
The U.S. overdose death rate fell by 24.4% between 2023 and 2024, dropping to 23.7 deaths per 100,000 people, according to a study published June 2, 2026 in the journal Addiction. Researchers from the University of California San Diego found this marks the first recorded decline across all four waves of the nation's overdose crisis, a shift they describe as "historic."
"We are seeing a historic shift in the overdose crisis. But this is not the end," said Joseph Friedman, MD, PhD, MPH, resident physician in the Department of Psychiatry at UC San Diego School of Medicine and the study's first author. "The substances involved are changing, some parts of the crisis are still growing, presenting new challenges. We need to avoid interpreting declining national numbers as a sign that the crisis has been solved."
The analysis drew on national overdose mortality data from the CDC (搜索)'s WONDER database, examining every recorded overdose death in the United States between 1999 and 2024.
Fentanyl declines drive national improvement
The nationwide decrease was primarily linked to falling deaths involving illicit fentanyl, both alone and in combination with stimulants. Deaths involving fentanyl without stimulants fell from 31,193 in 2023 to 19,673 in 2024. Meanwhile, deaths involving fentanyl combined with stimulants such as methamphetamine or cocaine dropped from 41,583 to 28,062.
Researchers describe the U.S. overdose epidemic as unfolding in four waves: prescription opioids, heroin, fentanyl, and — most recently — fentanyl combined with stimulants. The fourth wave, considered especially lethal due to polysubstance use, declined for the first time in 2024.
Emerging threats: stimulants and xylazine
Despite the encouraging headline numbers, the study identified clear warning signs. Deaths involving stimulants without fentanyl continued their upward trajectory, rising from 18,142 deaths in 2023 to 18,907 in 2024. These deaths accounted for 17.3% of overdose fatalities in 2023 but grew to 23.8% in 2024.
Xylazine, a veterinary sedative increasingly found in the illicit drug supply, was also implicated in a growing share of fentanyl-related overdose deaths.
Researchers warn that if these trends continue, stimulants such as methamphetamine and cocaine may soon surpass opioids as the defining addiction-related public health challenge in the U.S.
"Overdose deaths are only one part of the picture," said Steffanie Strathdee, PhD, senior author of the study and professor of medicine at UC San Diego School of Medicine. "Stimulants are also associated with long-term cardiovascular, neurological and psychiatric harms that can devastate individuals and communities."
Persistent racial and ethnic disparities
The study documented substantial racial and ethnic disparities that remain severe. Non-Hispanic Black individuals experienced the largest decline in overdose death rates between 2023 and 2024, with rates falling by 29.3%. However, the overdose death rate for Black Americans remained more than 1.5 times higher than the national average in 2024.
Non-Hispanic American Indian and Alaska Native populations had the highest overdose death rate of any group studied, at 50.8 deaths per 100,000 people — more than double the national average. Cocaine-related deaths disproportionately affected Black Americans, while methamphetamine-related deaths disproportionately affected American Indian and Alaska Native communities. Xylazine-related overdose deaths were also especially elevated among Black Americans.
Multifactorial causes and the road ahead
The researchers say the causes of the recent decline are likely complex and multifactorial. Possible explanations include a reduced number of susceptible individuals, greater awareness of fentanyl risks, expanded availability of naloxone, changes in drug use behavior, and possible disruptions in the illicit fentanyl supply chain. The authors caution that provisional 2024 mortality data could still change slightly as final records become available.
Even with the recent decline, approximately 80,000 people died from drug overdoses in the U.S. in 2024 — far more than would be expected if the country had overdose death rates comparable to Western Europe. Researchers say continued investment in addiction treatment, harm reduction programs, and targeted public health interventions will be essential to sustaining progress and reducing persistent inequities.
"National trends can improve while vulnerable communities continue to suffer disproportionately," Friedman said. "The next phase of the response needs to focus not only on lowering overall deaths, but on making sure those gains reach the populations that have been hit hardest."